This well-conducted review concluded that thiazolidinediones, particularly pioglitazone, were associated with an increased risk of bladder cancer among adults with type 2 diabetes. The authors acknowledged the limitations of the evidence base and that the incidence of bladder cancer may have been underestimated. The authors' conclusions reflect the evidence presented and are likely to be reliable.
Study selection
Randomised controlled trials (RCTs), cohort studies and case-control studies that compared thiazolidinedione exposure with no thiazolidinedione exposure in adults (not defined) with type 2 diabetes were eligible for inclusion. The outcome of interest was incidence of bladder cancer. Most of the participants received pioglitazone; rosiglitazone was also commonly used. Most studies seemed to use only a thiazolidinedione; some also reported using insulin, sulphonylurea and/or metformin. No participant characteristics were reported beyond the inclusion criteria.
Two reviewers independently selected studies for the review. Disagreements were resolved by discussion or consultation with a third reviewer.
Assessment of study quality
The quality of RCTs was assessed using the Cochrane risk of bias tool. Observational studies were assessed using the Newcastle-Ottawa Scale; a score of 5 or less out of 8 was considered to indicate a high risk of bias.
Two reviewers performed the quality assessment; it was not specifically stated that the assessments were independent.
Data extraction
Two reviewers independently extracted data to enable calculation of risk ratios (RR) and 95% confidence intervals (CI); disagreements were resolved by discussion or consultation with a third reviewer. Where necessary, authors were contacted for additional information.
Methods of synthesis
Pooled risk ratios and 95% CI were calculated using an inverse variance Mantel-Haenszel random-effects metaanalysis; adjusted risk ratios were used when derived from observational studies (variables differed across studies) and unadjusted when derived from RCTs. Heterogeneity was assessed using the Ι² statistic. The level of heterogeneity was classified as low (≤25%), moderate (>25% to 50%) or high (>50% to 75%). Heterogeneity was explored where Ι² was greater than 25% and pooling was not undertaken where Ι² was more than 75%. The primary analysis was an evaluation of pioglitazone stratified by study design. Secondary analyses were of rosiglitazone and any thiazolidinedione. Subgroup analyses of pioglitazone or rosiglitazone monotherapy were planned but could not be conducted. The authors stated that there were too few studies to assess publication bias.
